NewAmsterdam Pharma Company N.V. (NAMS) News
Track canonical SquawkNews coverage tagged to NAMS, NewAmsterdam Pharma Company N.V.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial for preclinical Alzheimer’s
NewAmsterdam Pharma announced dosing the first participant in SPINOZA, a Phase 2b trial testing obicetrapib in preclinical Alzheimer’s disease.Key Highlights:Original SEC Filing: NewAmsterdam Pharma Co N.V. [ NAMS ] - 8-
REGULATION | Sep 29, 2026, 12:33 PM UTC
L
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-- The study will evaluate changes in blood-based bi
NEWS | Sep 29, 2026, 12:09 PM UTC
M
NewAmsterdam Pharma wins EU approval for obicetrapib drugs
European Commission marketing authorizations were granted for Ubeslo and Evlarco, both containing obicetrapib. The company said these are the first global approvals for obicetrapib.
REGULATION | Sep 21, 2026, 08:34 PM UTC
M
European Commission approves NewAmsterdam Pharma’s Ubeslo and Evlarco
TradingView News reports the European Commission approved NewAmsterdam Pharma’s Ubeslo and Evlarco.
REGULATION | Sep 21, 2026, 04:38 PM UTC
M
European Commission approves NewAmsterdam/Menarini obicetrapib therapies
European Commission approval granted for NewAmsterdam Pharma’s obicetrapib monotherapy (Ubeslo®) and obicetrapib plus ezetimibe fixed-dose combination (Evlarco®), per TradingView News.
REGULATION | Sep 21, 2026, 02:58 PM UTC
M
European Commission approves NewAmsterdam’s Ubeslo and Evlarco in EU
The European Commission approved Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination) for NewAmsterdam Pharma and Menarini, supported by Phase 3 BROADWAY, BROOKLYN and TANDEM
REGULATION | Sep 21, 2026, 01:03 PM UTC
L
NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch
Obicetrapib, a differentiated CETP inhibitor, is nearing key readouts from the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study, with plans for launch in 12—18 months. PREVAIL’s interim analysis is set for
EQUITY | Sep 09, 2026, 09:55 PM UTC
L
NAMS: Obicetrapib advances toward launch with pivotal PREVAIL and RUBIN trial milestones ahead
Obicetrapib, a differentiated CETP inhibitor, is nearing key milestones with the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study. The drug offers unique benefits over competitors, with interim PREVAIL resu
EQUITY | Sep 09, 2026, 08:56 PM UTC
L
HC Wainwright maintains NewAmsterdam Pharma price target at $52
HC Wainwright & Co. maintained its price target for NewAmsterdam Pharma at $52.00 per share, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
NewAmsterdam Pharma to participate in September investor conferences
NewAmsterdam Pharma Company N.V. said it will participate at upcoming investor conferences in September.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
NewAmsterdam Pharma to present at ESC Congress 2026
NewAmsterdam Pharma announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026.
GEOPOLITICS | Aug 26, 2026, 12:07 PM UTC
L
NAMS Initiated Outperform and $58 PT @ BMO
NAMS Initiated Outperform and $58 PT @ BMO
EQUITY | Jul 21, 2026, 12:42 PM UTC
L
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.
EQUITY | Jun 30, 2026, 03:33 PM UTC